People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...

Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

Using fermentation, University of Alberta researchers have come up with a way to produce higher amounts of a healthy fatty ...

A £1.65 million treatment has been approved for use for some NHS patients, offering hope of a cure to those with an inherited ...

According to the National Capital Poison Center, a not-for-profit poison control organization, at least 85 drugs—including ...

The UK is poised to lead the next great leap in agriculture, with gene-editing technology offering a lifeline to a ...

As scientists grapple with the implications of a CRISPR-baby world, a new analysis took an unusual approach to analyzing the risks and benefits of germline editing. For one, it was completely inside a ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...

The X contains more genes related to brain function than does any other chromosome. “The X chromosome may be a treasure trove of genes that influence cognition, and these could be therapeutic targets, ...

The articles in this special issue highlight the diversity and complexity of research into reproductive health, including the need for a better understanding of the fundamental biology of reproduction ...